Prospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 21, 2025; 31(11): 102795
Published online Mar 21, 2025. doi: 10.3748/wjg.v31.i11.102795
Attenuation imaging for hepatic steatosis in chronic hepatitis B vs metabolic dysfunction-associated steatotic liver disease
Xue-Qi Li, Guang-Wen Cheng, Iwaki Akiyama, Xian-Jue Huang, Jing Liang, Li-Yun Xue, Yi Cheng, Masatoshi Kudo, Hong Ding
Xue-Qi Li, Guang-Wen Cheng, Jing Liang, Li-Yun Xue, Yi Cheng, Hong Ding, Department of Ultrasound, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Iwaki Akiyama, Medical Ultrasound Research Center, Doshisha University, Kyoto 600-8586, Kyōto, Japan
Xian-Jue Huang, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China
Masatoshi Kudo, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka 577-8502, Japan
Co-first authors: Xue-Qi Li and Guang-Wen Cheng.
Co-corresponding authors: Masatoshi Kudo and Hong Ding.
Author contributions: Ding H and Kudo M contributed to study design; Li XQ and Cheng GW contributed to statistical analysis and interpretation of data; Li XQ, Cheng GW, Akiyama I, Huang XJ, Liang J, Xue LY, Cheng Y, Kudo M, Ding H contributed to data collection, manuscript draft and editing; All authors read and approved the final manuscript.
Supported by the National Natural Science Foundation of China, No. 82202185; and Shanghai Science and Technology Development Foundation, No. 22Y11911500.
Institutional review board statement: The prospective study was approved by the Medical Ethics Committee of Huashan Hospital of Fudan University (No. 2020-1204).
Clinical trial registration statement: This trial has been registered at Chinese Clinical Trial Registry, with the identifier No. ChiCTR2300069459.
Informed consent statement: All patients have signed informed consent.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong Ding, MD, PhD, Professor, Department of Ultrasound, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, No. 12 Urumqi Middle Road, Shanghai 200040, China. ding_hong@fudan.edu.cn
Received: November 5, 2024
Revised: January 25, 2025
Accepted: February 20, 2025
Published online: March 21, 2025
Processing time: 128 Days and 20.4 Hours
Core Tip

Core Tip: Our study demonstrated that for the same steatosis grade, the attenuation coefficient (AC) value was significantly higher in the metabolic dysfunction-associated steatotic liver disease (MASLD) group than that in the chronic hepatitis B group. AC effectively discriminated between the degree of steatosis in steatotic liver disease of various etiologies. In the MASLD group, to improve the ability to predict ≥ S2, a clinical model incorporating blood biochemical parameters and AC was established, with an area under the curve of 0.848. The predictive model demonstrated a sensitivity of 91.2% and a specificity of 71.8%.